As of Wednesday close, PDS Biotechnology Corporation’s (NASDAQ:PDSB) stock was up $0.35, moving up 5.95 percent to $6.23. The average number of shares traded per day over the past five days has been 923,720 shares. 3 times new highs have been achieved over the past 5 days, with a $0.92 gain in that time frame. In the last twenty days, the average volume was 561,855, while in the previous 50 days, it was 846,656.
Since last month, PDSB stock rose 9.11%. Shares of the company fell to $4.62 on 08/11/23, the lowest level in the past month. A 52-week high of $13.65 was reached on 01/03/23 after having rallying from a 52-week low of $2.89. Since the beginning of this year, PDSB’s stock price has dropped by -52.80% or -$6.97, and marked a new high 1 time. However, the stock has declined by -54.36% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
In the three months ended June 29, PDS Biotechnology Corporation’s quick ratio stood at 16.50, while its current ratio was 16.50, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.57, and the total debt-to-equity ratio was 0.57. Based on annual data, PDSB earned $1.32 million in gross profit and brought in $41.67 million in revenue.
In PDS Biotechnology Corporation’s quarter-end financial report for June 29, it reported total debt of $23.25 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected PDS Biotechnology Corporation to report -$0.35 quarterly earnings, the actual figure was -$0.37 per share, beating the consensus estimate by -5.70%. During the quarter, the company generated -$12.57 million in EBITDA. The liabilities of PDS Biotechnology Corporation were 31.31 million at the end of its most recent quarter ended June 29. The value of shareholders’ equity is $30.87 million.
Technical Picture
This quick technical analysis looks at PDS Biotechnology Corporation’s (PDSB) price momentum. With a historical volatility rate of 106.72%, the RSI 9-day stood at 66.02% on 16 August.
With respect to its five-day moving average, the current PDS Biotechnology Corporation price is up by +17.33% percent or $0.92. At present, PDSB shares trade +5.24% above its 20-day simple moving average and +5.24% percent above its 100-day simple moving average. However, the stock is currently trading approximately -4.59% below its SMA50 and +21.92% above its SMA200.
Stochastic coefficient K was 76.11% and Stochastic coefficient D was 51.04%, while ATR was 0.49. Given the Stochastic reading of 92.53% for the 14-day period, the RSI (14) reading has been calculated as 60.25%. As of today, the MACD Oscillator reading stands at 0.41, while the 14-day reading stands at 0.33.
Analyst Ratings
B. Riley Securities launched its rating on PDS Biotechnology Corporation (NASDAQ: PDSB) to a Buy in a note to investors on November 01, 2022. PDS Biotechnology Corporation (PDSB) has been rated Buy by analysts. According to 0 brokerage firms, PDSB is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate PDS Biotechnology Corporation stock as buy, with 7 recommending it as overweight.
With a median target price of $18.00, the current consensus forecast for the stock is $14.00 – $25.00. Based on these forecasts, analysts predict PDS Biotechnology Corporation (PDSB) will achieve an average price target of $19.14.
